VALN

Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Valneva SE following a CDC notice about adverse events related to its chikungunya vaccine, which led to a significant drop in the company's stock price.

Company Background: Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial financial recoveries for class members.

Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Valneva SE following reports of adverse health events related to its chikungunya vaccine, which led to a significant drop in the company's stock price.

CDC Involvement: The U.S. CDC is currently examining five hospitalizations for cardiac or neurologic issues in older adults after vaccination with Valneva's IXCHIQ vaccine, prompting concerns among investors.

Valneva's Chikungunya Vaccine Recommendation: The CDC's Advisory Committee on Immunization Practices (ACIP) has updated its recommendation for Valneva's IXCHIQ® vaccine, maintaining its use for adults traveling to chikungunya outbreak areas and suggesting it for those in elevated risk regions. A precaution was noted for individuals aged 65 and older due to reported serious adverse events, although no causal link to the vaccine was established.

Ongoing Safety Monitoring and Supply Efforts: Valneva has supplied approximately 80,000 doses of IXCHIQ® globally and continues to monitor safety closely, with no new serious adverse events reported since January 2025. The company is also responding to an ongoing chikungunya outbreak by supplying additional doses to affected regions, particularly prioritizing vaccination for older adults with comorbidities.